Cellectar Biosciences
CLRB
30 hedge funds and large institutions have $4.69M invested in Cellectar Biosciences in 2022 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 10 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
7% more capital invested
Capital invested by funds: $4.38M → $4.69M (+$313K)
0% more ownership
Funds ownership: 0.04% → 0.04% (+0%)
27% less funds holding
Funds holding: 41 → 30 (-11)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$549K |
| 2 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$147K |
| 3 |
1WM
1900 Wealth Management
San Antonio,
Texas
|
+$35K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$4.38K |
| 5 |
Renaissance Technologies
New York
|
+$4.03K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$162K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$121K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$109K |
| 4 |
Two Sigma Advisers
New York
|
-$62.1K |
| 5 |
Two Sigma Investments
New York
|
-$43K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Osaic Holdings
Scottsdale,
Arizona
| $3K | – | – | – |
|
27
US Bancorp
Minneapolis,
Minnesota
| $2K | – | – | – |
|
28
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| $1K | – | – | – |
|
|
IA
29
IFP Advisors
Tampa,
Florida
| $1K | – | – | – |
|
|
30
Morgan Stanley
New York
| – | -$162K | -923 | Closed |
|
|
31
Citadel Advisors
Miami,
Florida
| – | -$109K | -549 | Closed |
|
|
32
Two Sigma Investments
New York
| – | -$43K | -217 | Closed |
|
33
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$33K | -168 | Closed |
|
34
T. Rowe Price Associates
Baltimore,
Maryland
| – | -$28K | -139 | Closed |
|
|
VF
35
Virtu Financial
New York
| – | -$25K | -125 | Closed |
|
36
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| – | -$13K | -67 | Closed |
|
37
Jane Street
New York
| – | -$9K | -47 | Closed |
|
|
TSS
38
Two Sigma Securities
New York
| – | -$9K | -47 | Closed |
|
CLRB Hedge Fund Activity: Q1 2022 in Review
30 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Cellectar Biosciences (CLRB) for Q1 2022, worth a combined $4.69M — up 7.2% from $4.38M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of CLRB and 0 opened new positions — a net loss of 10 holders — while 4 trimmed existing stakes and 6 added.
The largest buyer was AIGH Capital Management, adding an estimated $549K. The largest seller was Morgan Stanley, exiting entirely with an estimated $162K sold.
- 30 institutional investors held Cellectar Biosciences (CLRB) as of Q1 2022, down from 41 in Q4 2021.
- Funds reported $4.69M of Cellectar Biosciences stock for Q1 2022, up 7.2% quarter-over-quarter.
- 0 funds opened new Cellectar Biosciences positions in Q1 2022 and 10 closed out, a net change of -10 holders.
- The largest Cellectar Biosciences buyer in Q1 2022 was AIGH Capital Management, an estimated $549K added.
- The largest Cellectar Biosciences seller in Q1 2022 was Morgan Stanley, an estimated $162K sold.
Based on aggregated 13F filings for Q1 2022.